Aytu BioPharma expands, extends lending agreement with Eclipse

Aytu BioPharma (AYTU) expanded and extended its lending agreement with Eclipse Business Capital, providing added working capital flexibility as the Company prepares for the commercial launch of EXXUA extended-release tablets. Gepirone is a new chemical entity, and EXXUA is the selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration for the treatment of major depressive disorder in adults. Earlier this month, Aytu announced an exclusive agreement to commercialize EXXUA in the United States entering the Company into the over $22 billion United States prescription MDD market. Over 340 million antidepressant prescriptions were written in 2024 in the United States, yet significant unmet needs remain considering the unacceptable side effects associated with current therapeutics. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.